Back to Search
Start Over
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
- Source :
-
Neuro-oncology advances [Neurooncol Adv] 2021 Feb 15; Vol. 3 (1), pp. vdab007. Date of Electronic Publication: 2021 Feb 15 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: In primary central nervous system lymphoma (PCNSL), small enhancing lesions can persist after treatment. It is unknown whether a difference in response category (complete response [CR], complete response unconfirmed [CRu], or partial response [PR]) reflects survival. We aimed to determine the value of a central radiology review on response assessment and whether the extent of response influenced progression-free and/or overall survival.<br />Methods: All patients in the HOVON 105/ALLG NHL 24 study with at least a baseline MRI and one MRI made for response evaluation available for central review were included. Tumor measurements were done by 2 independent central reviewers, disagreements were adjudicated by a third reviewer. Crude agreement and interobserver agreement (Cohen's kappa) were calculated. Differences in progression-free and overall survival between different categories of response at the end-of-protocol-treatment were assessed by the log-rank test in a landmark survival-analysis.<br />Results: Agreement between the central reviewers was 61.7% and between local and central response assessment was 63.0%. Cohen's kappa's, which corrects for expected agreement, were 0.44 and 0.46 (moderate), respectively. Progression agreement or not was 93.3% (kappa 0.87) between local and central response assessment. There were no significant differences in progression-free and overall survival between patients with CR, CRu, or PR at the end-of-protocol-treatment, according to both local and central response assessment.<br />Conclusions: Reliability of response assessment (CR/CRu/PR) is moderate even by central radiology review and these response categories do not reliably predict survival. Therefore, primary outcome in PCNSL studies should be survival rather than CR or CR/CRu-rate.<br /> (© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
Details
- Language :
- English
- ISSN :
- 2632-2498
- Volume :
- 3
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Neuro-oncology advances
- Publication Type :
- Academic Journal
- Accession number :
- 33615224
- Full Text :
- https://doi.org/10.1093/noajnl/vdab007